The protective effect of resveratrol on tau hyperphosphorylation was abolished upon coadministration with a selective PI3K inhibitor, LY294002, suggesting the crucial role of the AMPK/PI3K/Akt signaling pathway in its mechanism of action instead of PP2A.[176] Additional evidence shows the promising role of resveratrol in the therapy of AD and related tauopathies. Here, MAPT is linked to tauopathy.